Ena/VASP-EVH1 inhibition prevents chemotaxis and metastasis by blocking the EVH1–WAVE2 interaction
Abstract
Cancer therapy would benefit from suppressing cancer cell motility in the process of metastasis. Such directed cell migration relies on the propulsive force established by the filamentous actin network within lamellipodia. Proteins of the Ena/VASP family and the WAVE regulatory complex orchestrate lamellar protrusions and therefore provide promising targets for pharmacological interventions. Here, we report a cross-talk between Ena/VASP proteins and WAVE2 that is important for cancer cell extravasation. Mutating the EVH1 domain recognition motif in WAVE2 abrogates chemotaxis of triple-negative MDA-MB-231 breast cancer cells and reduces their extravasation in a zebrafish model. In pilot experiments, orthotopic implantation of these cells into mice led to a reduction in macrometastasis, resulting in prolonged survival. Similarly, intervention by an Ena/VASP-EVH1 inhibitor also reduced metastasis in vivo. Our results suggest that pharmacological interference with the Ena/VASP–WAVE2 interaction may thus reduce metastasis.
Article Details
Journal Info
Proceedings of the National Academy of Sciences
National Academy of Sciences
Authors (14)
Matthias Müller
PROSION Therapeutics
Matthias Barone
Leibniz-Forschungsinstitut für Molekulare Pharmakologie
Maarten van Dinther
Oncode Institute, Department of Cell and Chemical Biology, Leiden University Medical Center
Kathrin Motzny
Leibniz-Forschungsinstitut für Molekulare Pharmakologie
Jiang Ren
Oncode Institute, Department of Cell and Chemical Biology, Leiden University Medical Center
Jenny Eichhorst
Leibniz-Forschungsinstitut für Molekulare Pharmakologie
Dominik Albat
PROSION Therapeutics
Slim Chiha
PROSION Therapeutics
Martin Lehmann
Department of Molecular Physiology and Cell Biology, Leibniz Forschungsinstitut für Molekulare Pharmakologie
Rudolf Volkmer
Leibniz-Forschungsinstitut für Molekulare Pharmakologie
Hartmut Oschkinat
Leibniz-Forschungsinstitut für Molekulare Pharmakologie, Robert-Rössle-Straße 10, 13125 Berlin, Germany
Hans-Günther Schmalz
PROSION Therapeutics
Peter ten Dijke
Oncode Institute, Department of Cell and Chemical Biology, Leiden University Medical Center
Ronald Kühne
PROSION Therapeutics